Hamel Associates, Inc. Novartis Ag Transaction History
Hamel Associates, Inc.
- $294 Million
- Q1 2025
A detailed history of Hamel Associates, Inc. transactions in Novartis Ag stock. As of the latest transaction made, Hamel Associates, Inc. holds 41,060 shares of NVS stock, worth $4.79 Million. This represents 1.56% of its overall portfolio holdings.
Number of Shares
41,060
Previous 8,680
373.04%
Holding current value
$4.79 Million
Previous $844,000
442.3%
% of portfolio
1.56%
Previous 0.27%
Shares
25 transactions
Others Institutions Holding NVS
# of Institutions
1,545Shares Held
141MCall Options Held
1.63MPut Options Held
1.82M-
Dodge & Cox San Francisco, CA11.8MShares$1.38 Billion0.81% of portfolio
-
Primecap Management CO Pasadena, CA10.4MShares$1.21 Billion0.98% of portfolio
-
Dimensional Fund Advisors LP Austin, TX8.61MShares$1 Billion0.25% of portfolio
-
Morgan Stanley New York, NY7.06MShares$823 Million0.06% of portfolio
-
Ken Fisher Fisher Asset Management, LLC | Camas, Wa6.76MShares$789 Million0.33% of portfolio
About NOVARTIS AG
- Ticker NVS
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,151,000,064
- Market Cap $251B
- Description
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...